Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Innovative Medicines Initiative

This page shows the latest Innovative Medicines Initiative news and features for those working in and with pharma, biotech and healthcare.

IMI calls for advancements in machine learning and digital clinical trials

IMI calls for advancements in machine learning and digital clinical trials

The Innovative Medicines Initiative (IMI) is pursing the development of machine learning and digital clinical trials with its latest round of funding. ... The funding, which comes from the EU’s Horizon 2020 research and innovative programme, will also

Latest news

  • The Harmony Alliance gathers to battle blood cancer

    At the 2. nd. general assembly based in Berlin, Germany last week, 120 representatives from the Innovative Medicines Initiative’s ( IMI) Harmony Alliance all gathered to discuss achievements and objectives surrounding

  • Novartis and Bayer among backers for European big data project Novartis and Bayer among backers for European big data project

    Novartis, Bayer, Servier and Vifor Pharma are among those participating in BigData@Heart, a five-year, 19m project supported by the Innovative Medicines Initiative (IMI). ... and personalised medicines through advanced analytics.

  • IMI aims €130m at medical research's unanswered questions IMI aims €130m at medical research's unanswered questions

    The Innovative Medicines Initiative (IMI) is taking aim at some of drug development’s unanswered questions with its latest round of funding. ... medicines development, ”added Meulien.

  • Untreatable gonorrhoea on the march worldwide, says WHO Untreatable gonorrhoea on the march worldwide, says WHO

    WHO and Drugs for Neglected Diseases initiative (DNDi). ... In the past few years there has been a renewed urgency to tackle the issue of antibiotic resistance, including a collaboration between companies involved in the Innovative Medicines Initiative

  • Real-world evidence Real-world evidence

    With these effective measures and guidelines in place, the UK could be the best place in the world for the research and development of new, innovative medicines, benefiting the UK economy, ... Lilly, which has spent around $3bn on researching Alzheimer's

More from news
Approximately 5 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • A quest for innovative solutions A quest for innovative solutions

    A quest for innovative solutions. UCB looks to the future through a PRISM. ... The innovative Medicines Initiative (IMI), with 5.3bn invested in 90 projects, is a barometer of the industry’s deep dive into technology at a time when ageing populations

  • Opening up innovation Opening up innovation

    The Immunology Network is probably one of the most innovative and powerful tools that I use to drive innovation and proliferation between different parts of the business, but also between GSK ... It has also been very active in the European Commission's

  • The world is our laboratory The world is our laboratory

    In January we announced the start of phase I clinical trials in the UK and US, production of 400, 000 vaccine regimens and formation of Innovative Medicines Initiative-funded consortia to ... That said, there is a rising demand for innovative medicines

  • The Heart of the Matter 7: Reality Dawns The Heart of the Matter 7: Reality Dawns

    Likewise, European pharmacovigilance legislation implemented in 2012 means the European Medicines Agency (EMA) is now requesting post-marketing observational studies as part of its approval processes. ... In tandem, as the limitations of the ‘

  • The Heart of the Matter 7: Reality Dawns The Heart of the Matter 7: Reality Dawns

    Likewise, European pharmacovigilance legislation implemented in 2012 means the European Medicines Agency (EMA) is now requesting post-marketing observational studies as part of its approval processes. ... In tandem, as the limitations of the ‘

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

  • Innovative Medicines Initiative appoints executive director Innovative Medicines Initiative appoints executive director

    Innovative Medicines Initiative (IMI) has named Pierre Meulien as executive director, effective from September. ... Commenting on his appointment, Meulien said: “ I am delighted to have been selected to lead the second phase of the Innovative Medicines

  • IMI picks Ipsen's Marc de Garidel to chair governing board IMI picks Ipsen's Marc de Garidel to chair governing board

    The Innovative Medicines Initiative (IMI) has picked Ipsen's Marc de Garidel to take over as chair of its governing board from Roch Doliveux, who retired as CEO of UCB at ... Its second-phase IMI 2 programme aims to develop next generation vaccines,

  • IMI appoints new chair of scientific committee IMI appoints new chair of scientific committee

    Prof Maria Beatriz da Silva Lima has been elected chair of the Scientific Committee of the Innovative Medicines Initiative (IMI).

  • Hans Lennernas joins board of CMO Recipharm Hans Lennernas joins board of CMO Recipharm

    Prof Lennernäs is currently a professor of biopharmaceuticals at Uppsala University in Sweden, where he manages an Innovative Medicines Initiative (IMI) project called OrBiTo, which aims to improve the delivery of ... We are very pleased to welcome a

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • The Heart of the Matter 7: Reality Dawns

    Likewise, European pharmacovigilance legislation implemented in 2012 means the European Medicines Agency (EMA) is now requesting post-marketing observational studies as part of its approval processes. ... In tandem, as the limitations of the 'gold

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia